Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H13N8O4S3.Na.5H2O |
| Molecular Weight | 566.565 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Na+].[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C([O-])=O
InChI
InChIKey=KHQJKXHCWOHDQD-HGUWTHONSA-M
InChI=1S/C14H14N8O4S3.Na.5H2O/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;;;;;;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);;5*1H2/q;+1;;;;;/p-1/t9-,12-;;;;;;/m1....../s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H14N8O4S3 |
| Molecular Weight | 454.507 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
| Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
| Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
| Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
280.9 μg/mL |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
509.9 μg × h/mL |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.01 h |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: |
healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (14.3%) Sources: |
1.5 g 8 times / day multiple, intravenous Highest studied dose Dose: 1.5 g, 8 times / day Route: intravenous Route: multiple Dose: 1.5 g, 8 times / day Sources: |
unhealthy, 21-34 years n = 4 Health Status: unhealthy Condition: endocarditis Age Group: 21-34 years Sex: M+F Population Size: 4 Sources: |
|
1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: |
healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: |
Other AEs: Pseudomembranous colitis... |
1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: |
Other AEs: Infection... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Rash | 14.3% Disc. AE |
4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: |
healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: |
| Pseudomembranous colitis | 1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: |
healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: |
|
| Infection | serious, 15 patients | 1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Double-blind comparison of phlebitis associated with cefazolin and cephalothin. | 1976 Jul |
|
| Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity. | 1978 May-Jun |
|
| IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera. | 1981 Jan |
|
| Antigenicity of beta-lactam antibiotic preparations: production of IgE antibodies to beta-lactam antibiotic and their cross-reaction within the antibiotic group. | 1982 |
|
| Cephalosporin-induced cholestatic jaundice. | 1982 Aug 7 |
|
| Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. | 1983 Oct |
|
| [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration]. | 1988 Jun |
|
| Pharmacological profile of the new anticonvulsant etazepine. | 1989 Apr |
|
| Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. | 1990 |
|
| Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources. | 1990 Jul |
|
| Use of charge-transfer complexation in the spectrophotometric analysis of certain cephalosporins. | 2001 Jul 6 |
|
| Potassium permanganate-glyoxal chemiluminescence system for flow injection analysis of cephalosporin antibiotics: cefalexin, cefadroxil, and cefazolin sodium in pharmaceutical preparations. | 2004 Sep 8 |
|
| Radiographic and computed tomographic evaluation of experimentally induced lung aspiration sites in dogs. | 2006 Dec |
|
| Attenuation of ischemia-reperfusion injury by ascorbic acid in the canine renal transplantation. | 2006 Dec |
|
| Epileptogenic activity of methicillin-resistant Staphylococcus aureus (MRSA) antibiotics in rats. | 2006 Oct |
|
| Effects of ascorbic Acid, alpha-tocopherol and allopurinol on ischemia-reperfusion injury in rabbit skeletal muscle: an experimental study. | 2007 |
|
| Pro-convulsant effect of cefazolin sodium against pentylenetetrazol- or picrotoxin-induced convulsions in mice. | 2007 Aug |
|
| [Simultaneous spectrophotometric determination of certain beta-lactam antibiotics in rabbit serum using multivariate calibration methods]. | 2007 Feb |
|
| Preclinical testing of the Levitronix Ultramag pediatric cardiac assist device in a lamb model. | 2007 May-Jun |
|
| Conventional and dense gas techniques for the production of liposomes: a review. | 2008 |
|
| [Physical and chemical characteristics of a new cefazolin sodium hydrate crystal]. | 2008 Aug |
|
| Interaction of beta-lactam antibiotics with the mitochondrial carnitine/acylcarnitine transporter. | 2008 Jun 17 |
|
| An intractable case of Pseudomonas aeruginosa infection after scleral buckling for rhegmatogenous retinal detachment. | 2008 Mar |
|
| How do porosity-inducing techniques affect antibiotic elution from bone cement? An in vitro comparison between hydrogen peroxide and a mechanical mixer. | 2008 Mar |
|
| Treatment of sinusitis with corticosteroids in combination with antibiotics in experimentally induced rhinosinusitis. | 2008 May |
|
| Cefazolin-induced hypoprothrombinemia. | 2008 May 1 |
|
| Trends in antibacterial use in US academic health centers: 2002 to 2006. | 2008 Nov 10 |
|
| [Retropharyngeal abscesses: a retrospective analysis of 10 patients]. | 2008 Sep-Oct |
|
| Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
| [Antibiotic susceptibility of pathogenic bacteria isolated from 893 children with lower respiratory infection in Guiyang]. | 2009 Dec |
|
| Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury. | 2009 Dec |
|
| Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat. | 2009 Dec 3 |
|
| Kinetic spectrofluorimetric determination of certain cephalosporins in human plasma. | 2009 Feb 15 |
|
| The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis. | 2009 Oct |
|
| Laser-induced silver nanoparticles on titanium oxide for photocatalytic degradation of methylene blue. | 2009 Oct 29 |
|
| Kinetic spectrophotometric determination of certain cephalosporins using oxidized quercetin reagent. | 2009 Sep 1 |
|
| Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits. | 2009 Sep 17 |
|
| Ectopic intrauterine device in the bladder of a pregnant woman. | 2010 |
|
| Histological characteristics of newly formed cementum in surgically created one-wall intrabony defects in a canine model. | 2010 Feb |
|
| Color selectivity of neurons in the posterior inferior temporal cortex of the macaque monkey. | 2010 Jul |
|
| Acute osteomyelitis of the acetabulum induced by Staphylococcus capitis in a young athlete. | 2010 Jun 18 |
|
| Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation. | 2010 Nov |
|
| Non-syndromic multiple supernumerary teeth in a family unit with a normal karyotype: case report. | 2010 Nov 5 |
|
| Periodontal regeneration capacity of equine particulate bone in canine alveolar bone defects. | 2010 Oct |
|
| Investigation of the toxic functional group of cephalosporins by zebrafish embryo toxicity test. | 2010 Oct |
|
| Sensitive chemiluminescence determination of thirteen cephalosporin antibiotics with luminol-copper(II) reaction. | 2010 Oct |
|
| Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives. | 2010 Oct |
|
| Piezoelectric immunosensors for the detection of individual antibiotics and the total content of penicillin antibiotics in foodstuffs. | 2014 Mar |
|
| Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. | 2015 Mar |
|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible
gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours
Route of Administration:
Other
Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 20:00:09 UTC 2022
by
admin
on
Sat Dec 17 20:00:09 UTC 2022
|
| Record UNII |
XLJ4VSY381
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
115850-11-8
Created by
admin on Sat Dec 17 20:00:10 UTC 2022 , Edited by admin on Sat Dec 17 20:00:10 UTC 2022
|
PRIMARY | |||
|
SUB33474
Created by
admin on Sat Dec 17 20:00:10 UTC 2022 , Edited by admin on Sat Dec 17 20:00:10 UTC 2022
|
PRIMARY | |||
|
23678598
Created by
admin on Sat Dec 17 20:00:10 UTC 2022 , Edited by admin on Sat Dec 17 20:00:10 UTC 2022
|
PRIMARY | |||
|
XLJ4VSY381
Created by
admin on Sat Dec 17 20:00:10 UTC 2022 , Edited by admin on Sat Dec 17 20:00:10 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |